Pfizer Inc Asset Resilience Ratio
Pfizer Inc asset resilience ratio. Pfizer Inc (PFE) has an Asset Resilience Ratio of 5.33% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pfizer Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pfizer Inc (1999–2025)
Asset resilience ratio of Pfizer Inc from 1999 to 2025. This chart shows how Pfizer Inc's Asset Resilience Ratio has changed over time. Read PFE liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pfizer Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Pfizer Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.72 Billion | 5.33% |
| Total Liquid Assets | $10.72 Billion | 5.33% |
Asset Resilience Insights
- Limited Liquidity: Pfizer Inc maintains only 5.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pfizer Inc Industry Peers by Asset Resilience Ratio
Compare Pfizer Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Pfizer Inc Asset Resilience Ratio by Year (1999–2025)
Pfizer Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Pfizer Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.53% | $13.60 Billion | $208.16 Billion | -3.06pp |
| 2024-12-31 | 9.60% | $20.48 Billion | $213.40 Billion | +3.99pp |
| 2023-12-31 | 5.60% | $12.69 Billion | $226.50 Billion | -5.92pp |
| 2022-12-31 | 11.53% | $22.73 Billion | $197.21 Billion | -5.59pp |
| 2021-12-31 | 17.12% | $31.07 Billion | $181.48 Billion | +9.20pp |
| 2020-12-31 | 7.92% | $12.22 Billion | $154.23 Billion | +2.16pp |
| 2019-12-31 | 5.76% | $9.65 Billion | $167.49 Billion | -6.05pp |
| 2018-12-31 | 11.81% | $18.83 Billion | $159.42 Billion | +0.18pp |
| 2017-12-31 | 11.64% | $19.99 Billion | $171.80 Billion | +1.24pp |
| 2016-12-31 | 10.40% | $17.85 Billion | $171.62 Billion | -1.33pp |
| 2015-12-31 | 11.73% | $19.65 Billion | $167.46 Billion | -7.63pp |
| 2014-12-31 | 19.36% | $32.78 Billion | $169.27 Billion | +1.80pp |
| 2013-12-31 | 17.56% | $30.23 Billion | $172.10 Billion | +5.55pp |
| 2012-12-31 | 12.01% | $22.32 Billion | $185.80 Billion | -0.34pp |
| 2011-12-31 | 12.35% | $23.22 Billion | $188.00 Billion | -1.12pp |
| 2010-12-31 | 13.47% | $26.28 Billion | $195.01 Billion | +2.21pp |
| 2009-12-31 | 11.27% | $23.99 Billion | $212.95 Billion | -8.18pp |
| 2008-12-31 | 19.44% | $21.61 Billion | $111.15 Billion | +0.30pp |
| 2007-12-31 | 19.15% | $22.07 Billion | $115.27 Billion | -3.40pp |
| 2006-12-31 | 22.54% | $25.89 Billion | $114.84 Billion | +5.55pp |
| 2005-12-31 | 16.99% | $19.98 Billion | $117.56 Billion | +2.37pp |
| 2004-12-31 | 14.62% | $18.09 Billion | $123.68 Billion | +5.69pp |
| 2003-12-31 | 8.93% | $10.43 Billion | $116.78 Billion | -14.09pp |
| 2002-12-31 | 23.02% | $10.67 Billion | $46.36 Billion | +3.67pp |
| 2001-12-31 | 19.36% | $7.58 Billion | $39.15 Billion | +2.16pp |
| 2000-12-31 | 17.20% | $5.76 Billion | $33.51 Billion | -0.80pp |
| 1999-12-31 | 18.00% | $3.70 Billion | $20.57 Billion | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more